Menzo Havenga

8.3k total citations · 1 hit paper
95 papers, 6.0k citations indexed

About

Menzo Havenga is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Menzo Havenga has authored 95 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Genetics, 53 papers in Molecular Biology and 38 papers in Oncology. Recurrent topics in Menzo Havenga's work include Virus-based gene therapy research (71 papers), CAR-T cell therapy research (37 papers) and Viral Infectious Diseases and Gene Expression in Insects (34 papers). Menzo Havenga is often cited by papers focused on Virus-based gene therapy research (71 papers), CAR-T cell therapy research (37 papers) and Viral Infectious Diseases and Gene Expression in Insects (34 papers). Menzo Havenga collaborates with scholars based in Netherlands, United States and United Kingdom. Menzo Havenga's co-authors include Jaap Goudsmit, Angelique A. C. Lemckert, Dan H. Barouch, Ronald Vogels, Lennart Holterman, Diana M. Lynch, Jerome Custers, Peter Abbink, Michelle A. Lifton and Darci A. Gorgone and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Menzo Havenga

94 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer

2008 500 citations Simon N. Waddington, John H. McVey et al. Cell profile →

Peers

Countries citing papers authored by Menzo Havenga

Since Specialization

Citations

This map shows the geographic impact of Menzo Havenga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Menzo Havenga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Menzo Havenga more than expected).

Fields of papers citing papers by Menzo Havenga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Menzo Havenga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Menzo Havenga. The network helps show where Menzo Havenga may publish in the future.

Co-authorship network of co-authors of Menzo Havenga

This figure shows the co-authorship network connecting the top 25 collaborators of Menzo Havenga. A scholar is included among the top collaborators of Menzo Havenga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Menzo Havenga. Menzo Havenga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective 2022 ·Journal of Molecular Medicine ·Julian Tristan Schwartze, Menzo Havenga, Wilfried A.M. Bakker, Angela C. Bradshaw, Stuart A. Nicklin	24
2	Stable, high yield expression of gp145 Env glycoprotein from HIV-1 in mammalian cells 2021 ·Biologicals ·(unknown), (unknown), Stephen Whitney, Wilfried A.M. Bakker, (unknown), (unknown), (unknown), Menzo Havenga	3
3	STEP® vectors for rapid generation of stable transfected CHO cell pools and clones with high expression levels and product quality homogeneity of difficult-to-express proteins 2021 ·Protein Expression and Purification ·(unknown), Remco A. Spanjaard, (unknown), (unknown), Lars Køber, Yiding Wang, (unknown), (unknown), (unknown), (unknown), Menzo Havenga, Wilfried A.M. Bakker	2
4	First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1 2018 ·PLoS ONE ·Kathryn E. Stephenson, Michael C. Keefer, Catherine A. Bunce, (unknown), Peter Abbink, Lori F. Maxfield, George H. Neubauer, Joseph P. Nkolola, Lauren Peter, Christopher Lane, (unknown), (unknown), Angela Lombardo, (unknown), Menzo Havenga, Patricia Fast, John Treanor, Dan H. Barouch	28
5	Enhancing viral vaccine production using engineered knockout vero cell lines – A second look 2018 ·Vaccine ·(unknown), Jon Karpilow, (unknown), Fija M. Lagerwerf, Menzo Havenga, (unknown), Gert Gillissen, Angelique A. C. Lemckert, Baoming Jiang, Ralph A. Tripp, (unknown)	14
6	Challenges in Manufacturing Adenoviral Vectors for Global Vaccine Product Deployment 2014 ·Human Gene Therapy ·Jort Vellinga, (unknown), Agnieszka Lipiec, Dragomira Majhen, Angelique A. C. Lemckert, (unknown), P. M. Ives, (unknown), Jerome Custers, Menzo Havenga	63
7	Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys 2008 ·Journal of Virology ·Jinyan Liu, Bonnie A. Ewald, Diana M. Lynch, Matthew Denholtz, Peter Abbink, Angelique A. C. Lemckert, Angela Carville, Keith G. Mansfield, Menzo Havenga, Jaap Goudsmit, Dan H. Barouch	90
8	Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer 2008 ·Journal of Virology ·Alan L. Parker, Simon N. Waddington, Suzanne M. K. Buckley, Jerome Custers, Menzo Havenga, Nico van Rooijen, Jaap Goudsmit, John H. McVey, Stuart A. Nicklin, Andrew H. Baker	66
9	A critical role for the adenovirus serotype 5 hexon in liver gene transfer 2008 ·Human Gene Therapy ·Simon N. Waddington, John H. McVey, David Bhella, Alan L. Parker, (unknown), (unknown), (unknown), Suzanne M. K. Buckley, Jenny A. Greig, Laura Denby, Jerome Custers, (unknown), Ivo M.B. Francischetti, Robson Q. Monteiro, Dan H. Barouch, Nico van Rooijen, Claudio Napoli, Menzo Havenga, Stuart A. Nicklin, Andrew H. Baker	1
10	Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer breakdown → 2008 ·Cell ·Simon N. Waddington, John H. McVey, David Bhella, Alan L. Parker, (unknown), Hideko Atoda, (unknown), Suzanne M. K. Buckley, Jenny A. Greig, Laura Denby, Jerome Custers, Takashi Morita, Ivo M.B. Francischetti, Robson Q. Monteiro, Dan H. Barouch, Nico van Rooijen, Claudio Napoli, Menzo Havenga, Stuart A. Nicklin, Andrew H. Baker	500
11	Human CD4⁺ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus 2006 ·European Journal of Immunology ·Louise A. Veltrop‐Duits, Bianca Heemskerk, Claudia C. Sombroek, Tamara van Vreeswijk, Sophie Gubbels, René E. M. Toes, Cornelis J.M. Melief, Kees L. M. C. Franken, Menzo Havenga, Maarten J. D. van Tol, Marco W. Schilham	36
12	Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity 2004 ·The Journal of Immunology ·Dan H. Barouch, Maria Grazia Pau, Jerome Custers, Wouter Koudstaal, Stefan Kostense, Menzo Havenga, Diana M. Truitt, Shawn M. Sumida, Michael Kishko, Janelle C. Arthur, Birgit Korioth-Schmitz, Michael H. Newberg, Darci A. Gorgone, Michelle A. Lifton, Dennis Panicali, Gary J. Nabel, Norman L. Letvin, Jaap Goudsmit	313
13	An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity 2004 ·Vaccine ·Olga Ophorst, Stefan Kostense, Jaap Goudsmit, Rik L. de Swart, Sandra Verhaagh, Alexander N. Zakhartchouk, Marja van Meijer, Mieke Sprangers, Geert van Amerongen, Selma Yüksel, Albert D. M. E. Osterhaus, Menzo Havenga	63
14	CD4+ Th2 Cell Recognition of HLA-DR-Restricted Epitopes Derived from CAMEL: A Tumor Antigen Translated in an Alternative Open Reading Frame 2003 ·The Journal of Immunology ·(unknown), Martina Borghi, (unknown), Corlien A. Aarnoudse, Menzo Havenga, Peter I. Schrier, Susanne Osanto, Marieke Griffioen	40
15	A rapid method for immunotitration of influenza viruses using flow cytometry 2003 ·Journal of Virological Methods ·(unknown), Maria Grazia Pau, (unknown), (unknown), (unknown), Menzo Havenga, Jaap Goudsmit, F. G. C. M. UytdeHaag, Giuseppe Marzio	24
16	Highly Efficient Transduction of Human Monocyte-Derived Dendritic Cells with Subgroup B Fiber-Modified Adenovirus Vectors Enhances Transgene-Encoded Antigen Presentation to Cytotoxic T Cells 2001 ·The Journal of Immunology ·Delphine Réa, Menzo Havenga, (unknown), Roger P.M. Sutmuller, Angelique A. C. Lemckert, Rob C. Hoeben, A. Bout, Cornelis J.M. Melief, Rienk Offringa	130
17	Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber 2001 ·Arthritis & Rheumatism ·Paulien H. Goossens, Menzo Havenga, Elsbet Pieterman, Angelique A. C. Lemckert, Ferdinand C. Breedveld, A. Bout, T. Huizinga	37
18	Strategies for improved antigen delivery into dendritic cells 2001 ·Trends in Molecular Medicine ·Delphine Réa, M.E. Johnson, Menzo Havenga, Cornelis J.M. Melief, Rienk Offringa	16
19	A Flow Cytometric Assay Enabling Specific Detection of the Human Lysosomal Enzyme, β-Glucocerebrosidase 1998 ·Analytical Biochemistry ·Menzo Havenga, Antonia Werner, Dinko Valerio, Helmuth H. G. van Es	4
20	A Flow Cytometric Assay for Lysosomal Glucocerebrosidase 1997 ·Analytical Biochemistry ·Helmuth H. G. van Es, Marlon R. Veldwijk, Menzo Havenga, Dinko Valerio	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact